Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 25, 2025 - Fresenius Kabi announced the FDA approval of Conexxence (denosumab-bnht), biosimilar to Amgen’s Prolia® (denosumab).
Download PDF
Return to publications
